<?xml version="1.0" encoding="UTF-8"?>
<p id="par0030">The performance during the first 48 h of the admission of any of the following virological determinations in respiratory samples (exudate or nasopharyngeal aspirate):
 <list list-type="simple" id="lis0005">
  <list-item id="lsti0005">
   <label>(a)</label>
   <p id="par0035">Multiplex polymerase chain reaction panel (mPCR) and subsequent visualisation using low-density 
    <italic>arrays</italic> with CLART® technology (Clart® Pneumovir, Genómica S.A.U., Madrid, Spain), which allows the detection of the following respiratory viruses: respiratory syncytial virus (VRS) A and B, influenza A (subtypes H1N1/2009, H1N1 and H3N2), B and C, rhinovirus, adenovirus, metapneumovirus A and B, parainfluenza 1, 2, 3 and 4, bocavirus and coronavirus.
   </p>
  </list-item>
  <list-item id="lsti0010">
   <label>(b)</label>
   <p id="par0040">Rapid diagnostic tests (RDT): antigenic detection by VRS TRU RSV® (Meridian Bioscience Inc., Palex Diagnóstica, Madrid, Spain) or isothermal amplification of influenza virus (Alere-i, Abbot, Spain) of influenza virus, with a positive result if not performed, and mPCR.</p>
  </list-item>
 </list>
</p>
